A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC.
- DOI
- 10.1177/17588359261483551
- Published
- 2026
- Container
- Therapeutic advances in medical oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1177/17588359261483551,
title = {A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC.},
author = {Yoshioka H and Mori M and Katakami N and Yokoyama T and Kaneda H and Matsumoto H and Tamiya M and Yamamoto K and Huang CL},
year = {2026},
journal = {Therapeutic advances in medical oncology},
doi = {10.1177/17588359261483551},
url = {https://doi.org/10.1177/17588359261483551}
}RIS
TY - JOUR TI - A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC. AU - Yoshioka H AU - Mori M AU - Katakami N AU - Yokoyama T AU - Kaneda H AU - Matsumoto H AU - Tamiya M AU - Yamamoto K AU - Huang CL PY - 2026 JO - Therapeutic advances in medical oncology DO - 10.1177/17588359261483551 UR - https://doi.org/10.1177/17588359261483551 ER -
APA
H, Y., M, M., N, K., T, Y., H, K., H, M., M, T., K, Y., & CL, H. (2026). A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC.. Therapeutic advances in medical oncology. https://doi.org/10.1177/17588359261483551
Source records
- pubmed · retrieved 2026-09-25T12:52:08.456Z